We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
George Thanassoulis
Reducing lipoprotein(a) by 65.7 mg/dL may have the same effect on clinical outcomes as a reduction in LDL to 38.67 mg/dL, according to a Mendelian randomization analysis published in JAMA Cardiology.
Claudia Lamina, PhD, of the division of genetic epidemiology at the Medical University of Innsbruck in Austria and of the division of genetic epidemiology at the Institute for Medical Biometry and Statistics at University of Freiburg in Germany, and Florian Kronenberg, MD, professor at the Medical University of Innsbruck, and colleagues analyzed data from 13,781 patients from the Lp(a)-GWAS-Consortium from five studies, 20,793 cases of CHD and 27,540 controls.
The mean age of the patients in four of the five studies was 51 to 59 years; the mean age of patients from the fifth study was 32 years. The studies comprised between 51% and 55% women.
Lp(a) concentrations were measured at the same laboratory and ranged from 11 mg/dL to 12 mg/dL. The data set also included 27 single nucleotide polymorphisms on Lp(a).
A reduction in Lp(a) by 65.7 mg/dL (95% CI, 46.3-88.3) would result in a 45% lifetime risk reduction for CHD and a 22% reduction in short-term risk, according to the researchers.
“These results have important implications for the planning of randomized clinical trials of drugs that target Lp(a) concentrations,” the researchers wrote. “First, these drugs need to have a pronounced Lp(a) lowering potential, which we estimated to be 65.7 mg/dL, but more than 100 mg/dL might be an overestimate. ... Second, the upcoming first trials should include patients with Lp(a) greater than 100 mg/dL at baseline to achieve an Lp(a) concentration less than 30 mg/dL by treatment. Third, the Lp(a) assay used for identification of patients for treatment have to be well-standardized to avoid an overestimation or underestimation of Lp(a) concentrations and thereby an inappropriate recruitment of patients.”
Reducing lipoprotein(a) by 65.7 mg/dL may have the same effect on clinical outcomes as a reduction in LDL to 38.67 mg/dL, according to a Mendelian randomization analysis published in JAMA Cardiology.
Source: Adobe Stock
“Notwithstanding these limitations, it is nonetheless remarkable that we can validate novel therapeutic targets such as Lp(a) and also resolve key trial parameters prior to starting any [randomized controlled trial], based on such genetic studies,” George Thanassoulis, MD, MSc, FRCPC, director of preventive and genomic cardiology at McGill University Health Centre in Montreal and assistant professor of medicine at McGill University, wrote in a related editorial. “Mendelian randomization has been instrumental in the resurgence of Lp(a) in the cardiovascular community, arguably more so than for any other biomarker. Indeed, much of the current understanding of Lp(a) has been derived from such studies.” – by Darlene Dobkowski
Disclosures:Lamina reports no relevant financial disclosures. Kronenberg reports he received personal fees from Amgen and Kaneka. Thanassoulis reports he participated in advisory boards for Amgen, Ionis and Sanofi-Regeneron; participated in speaker bureaus for Amgen and Sanofi, and received grant funding from Ionis and Servier.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.